An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies

Aurora Therapeutics, the first bespoke CRISPR startup, lays off staff and drops its PKU program as CEO Ed Kaye exits, months after a $16M seed round.

Raccontata daendpoints.news